HLB Science announced on the 2nd that it has signed a research agreement with NodeCure, a company possessing technology for developing microbiome-based metabolic and immune disease therapeutics.
NodeCure was founded in 2021 by Professor Jonghwan Park of Chonnam National University College of Veterinary Medicine and conducts research on pharmaceutical materials based on the microbiome. Using these materials, the company is conducting research to develop treatments for cancer, infectious diseases, metabolic, and immune disorders. The microbiome is a term combining microbe and biome, referring to the community of microorganisms residing in the human body.
Through this business agreement, HLB Science plans to conduct joint research with NodeCure in the microbiome field and review the scalability of new drug pipelines based on this technology.
HLB Science is currently developing 'DD-S052P,' an antibiotic for treating sepsis and superbugs, and is conducting Phase 1 clinical trials in France. On the 17th, it was finally selected as a project participant for the '2023 1st Health and Medical Technology R&D Project' led by the Ministry of Health and Welfare, receiving research funding of 2.75 billion KRW over the next three years.
Yoon Jongseon, CEO of HLB Science, stated, "Microbiome therapeutics, which apply the gut microbial ecosystem to treatment areas, are attracting attention as next-generation biopharmaceuticals because they have significantly fewer side effects than existing treatments and can offer new therapeutic methods. We will enhance corporate value through cooperation with NodeCure, which possesses outstanding technology and research capabilities in this field."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
